Stanford, CA – April 24, 2024 – In a discovery poised to fundamentally reshape our understanding of cancer immunology, scientists have unveiled a surprising, critical role for a protein long associated with red blood cell production in dampening the body’s immune response to cancer. The protein, erythropoietin (EPO), identified nearly four decades ago, has now been found to act as a stealthy suppressor of anti-tumor immunity, effectively shielding malignant cells from the very defenses designed to eradicate them.
Published online today in the prestigious journal Science, this groundbreaking research demonstrates that blocking EPO’s activity can transform previously "cold," or immune-resistant, liver tumors in mice into "hot" tumors, teeming with potent cancer-fighting immune cells. When this intervention was combined with an existing immunotherapy, the results were nothing short of remarkable: complete regression of established liver tumors in the majority of treated animals, which then lived for the entire duration of the experiment. In stark contrast, control animals succumbed to the disease within weeks.
“This is a fundamental breakthrough in our understanding of how the immune system is turned off and on in cancer,” declared Edgar Engleman, MD, PhD, a distinguished professor of pathology and medicine at Stanford University, and senior author of the study. “I could not be more excited about this discovery, and I hope treatments that target the mechanism we uncovered will quickly move forward to human trials.”
The lead author, basic life research scientist David Kung-Chun Chiu, PhD, spearheaded the intricate experimental work that culminated in this revelation. The implications of their findings extend far beyond liver cancer, suggesting a potential paradigm shift in treating a wide array of malignancies currently resistant to conventional immunotherapies.
Main Facts: A New Chapter for an Old Protein
The core discovery revolves around erythropoietin (EPO), a hormone traditionally known for its vital role in stimulating red blood cell formation – a function so well-established it has been the basis for treating anemia for decades. However, the new research illuminates a previously unrecognized function: EPO’s capacity to actively suppress the immune system’s ability to detect and destroy cancer cells.
Specifically, the Stanford team demonstrated that in "cold" tumors – those typically ignored by the immune system and resistant to many current immunotherapies – EPO is produced at elevated levels by the tumor cells themselves. This secreted EPO then acts on specialized immune cells called macrophages, instructing them to adopt an immunosuppressive phenotype. These reprogrammed macrophages, in turn, actively deter cancer-killing T cells from infiltrating the tumor microenvironment and dampen the activity of any T cells that do manage to gain entry.
The critical breakthrough came when researchers disrupted this EPO-mediated signaling pathway. By either preventing tumor cells from producing EPO or by blocking the EPO receptors on macrophages, they observed a dramatic transformation. Cold tumors became "hot," characterized by a robust influx of active T cells ready to combat the cancer. This sensitization to immune attack proved profoundly effective when combined with anti-PD-1 immunotherapy, a treatment that further empowers T cells to target malignant cells. The combination therapy led to durable, complete tumor regression in animal models, offering a compelling blueprint for future human treatments.
Chronology: From Red Blood Cells to Immune Checkpoints
The journey to this pivotal discovery is a testament to persistent scientific inquiry, bridging decades of research and challenging long-held assumptions about a familiar protein.
An Early, Unsettling Connection (Pre-2007):
For nearly 40 years, EPO’s primary identity was unequivocally linked to erythropoiesis – the production of red blood cells. Its therapeutic application to combat anemia, particularly in patients undergoing chemotherapy, became widespread. However, a troubling pattern began to emerge in clinical trials and observations prior to 2007. Studies revealed that administering exogenous EPO to anemic cancer patients, while boosting red blood cell counts, often had an adverse side effect: it accelerated tumor growth and worsened patient outcomes.
This connection was so striking and concerning that in 2007, the U.S. Food and Drug Administration (FDA) mandated a "black box warning" label on EPO-stimulating drugs, cautioning against their use in individuals with certain cancers. Researchers also noted a clear correlation between patient prognosis and the natural levels of EPO and its receptor (EPOR) within tumors – higher levels consistently predicted poorer outcomes.
“Those old reports showed clearly that the more EPO or EPOR there was in tumors, the worse off the patients were,” Dr. Engleman recounts. “But the connection between EPO and cancer immunity was never made until now. In fact, it took a long time and a lot of experiments to convince us that EPO plays a fundamental role in blocking the immune response to cancer, because EPO is so well established as a red blood cell growth factor.” The mechanism behind this detrimental effect remained a perplexing enigma, shrouded by EPO’s dominant identity as a hematopoietic factor.
The Quest for Immunotherapy Resistance (Post-2007):
The advent of immunotherapies, particularly checkpoint inhibitors targeting molecules like PD-1, revolutionized cancer treatment for some patients. By releasing the "brakes" on the immune system, these therapies enable T cells to recognize and attack cancer. Drugs like Keytruda (pembrolizumab) have transformed outcomes in melanoma, Hodgkin’s lymphoma, and certain lung cancers. Yet, a significant challenge persisted: a large majority of tumors, including common and deadly types like most liver, pancreatic, colon, breast, and prostate cancers, remained stubbornly resistant to these breakthrough treatments. These were the "cold" tumors, characterized by a lack of immune cell infiltration and activity.
Chiu’s Innovative Mouse Models (Recent Years):
To unravel the complexities of tumor development and resistance, Dr. David Kung-Chun Chiu embarked on developing sophisticated genome-editing techniques to create a series of robust mouse models for liver cancer. These models were meticulously engineered to recapitulate specific genetic mutations, histological features, and responses to approved therapies observed in distinct subtypes of human liver cancers. Tumor formation was induced either by injecting a combination of DNA encoding liver cancer-associated proteins into the animals’ tail veins or by implanting liver cancer cells directly into their livers. This comprehensive approach allowed for precise manipulation and observation of the tumor microenvironment.
The Serendipitous EPO Link (The "Aha!" Moment):
Within these carefully crafted models, the researchers focused on understanding why certain liver tumors were resistant to anti-PD-1 therapy. They observed that some combinations of genetic mutations led to the development of "cold" liver tumors, largely ignored by the immune system and unresponsive to anti-PD-1 treatment due to scarce T cell presence. In contrast, other mutations resulted in "hot" or "inflamed" tumors, replete with T cells and highly sensitive to anti-PD-1, leading to successful cancer eradication.
It was during this meticulous comparison that an unexpected pattern emerged: the "cold" tumors consistently displayed elevated levels of EPO compared to their "hot" counterparts. This observation immediately prompted the question: why would EPO be so prevalent in immune-resistant tumors? The answer, the team hypothesized, lay in the hypoxic (oxygen-poor) microenvironment often characteristic of cold tumors. Hypoxia is a known trigger for cancer cells to ramp up the production of proteins that, in turn, induce EPO production, ostensibly to stimulate more red blood cells to deliver oxygen.
“Hypoxia in tumors has been studied for decades,” Dr. Engleman explained. “It just didn’t dawn on anyone, including me, that EPO could be doing anything in this context other than serving as a red blood cell growth factor.” This unexpected correlation sparked the critical hypothesis that EPO might be more than just a red blood cell growth factor in the context of cancer; it might be an active participant in shaping the immune response.
Supporting Data: Unraveling the Mechanism
The initial observation of elevated EPO in cold tumors spurred a series of rigorous experiments to confirm the link and elucidate the underlying mechanism.
Epidemiological Confirmation:
The team first corroborated their mouse model findings by scrutinizing existing human cancer databases. Their analysis revealed a clear and consistent pattern: elevated levels of EPO were indeed correlated with poorer survival rates in patients suffering from various human cancers, including those of the liver, kidney, breast, colon, and skin. This critical step provided strong human correlative evidence for the rodent-based hypothesis.
Direct Experimental Manipulation:
To establish a causal link, the researchers then embarked on a series of ingenious experiments involving the direct manipulation of EPO production within tumor cells in their mouse models.
- Silencing EPO in cold tumors: When mutations that typically led to the development of cold tumors were modified to render the tumor cells unable to produce EPO, a dramatic transformation occurred. These formerly cold tumors now became "hot," infiltrated by immune cells.
- Overexpressing EPO in hot tumors: Conversely, hot tumors that had previously been successfully eradicated by the immune system were engineered to produce elevated levels of EPO. The result was equally striking: these tumors thrived, evading immune destruction.
These elegant experiments provided unequivocal evidence that EPO production by tumor cells directly dictates the immune status of the tumor, influencing its "hotness" or "coldness."
The Macrophage Connection: A Key Intermediary:
With the causal link established, the next crucial step was to pinpoint the exact mechanism by which EPO exerted its immunosuppressive effects. Through exhaustive research, the team uncovered a precise cellular crosstalk:
- Tumor cell secretion: In cold tumors, the tumor cells themselves synthesize and secrete EPO into the tumor microenvironment.
- Macrophage binding: This secreted EPO then binds to specific receptors (EPOR) located on the surface of immune cells known as macrophages, which are abundant within tumors.
- Immunosuppressive switch: Upon binding EPO, these macrophages undergo a critical phenotypic switch. They transform from potentially pro-inflammatory, anti-tumor cells into an immunosuppressive state.
- T-cell repulsion and dampening: In their immunosuppressive role, these EPO-activated macrophages actively "shoo away" cancer-killing T cells, preventing their infiltration into the tumor core. Furthermore, they actively dampen the activity of any T cells that do manage to enter the tumor, effectively neutralizing their anti-cancer potential.
Synergistic Therapeutic Power:
The profound importance of this EPO-moderated crosstalk between tumor cells and macrophages became unequivocally clear when the researchers investigated the combinatorial effect of simultaneously blocking the EPO signaling pathway and the anti-PD-1 pathway. This was the ultimate test of their hypothesis.
The results were compelling and statistically significant:
- Control and Anti-PD-1 Alone: In mice with cold liver tumors treated with a control substance or with anti-PD-1 monotherapy, none survived beyond eight weeks after tumor induction. This underscored the resistance of these tumors to conventional approaches.
- Blocking EPO Receptor on Macrophages: In a group of mice where macrophages were genetically modified to be unable to produce the EPO receptor, thus disrupting the EPO signaling pathway, 40% of the animals lived for the full 18-week duration of the experiment, at which point it was terminated. This demonstrated a significant improvement in survival simply by disabling the EPO-macrophage axis.
- Combined Therapy (Blocking EPO Receptor + Anti-PD-1): The most dramatic outcome was observed when anti-PD-1 treatment was administered to mice lacking the EPO receptor on their macrophages. In this cohort, an astonishing 100% of the animals lived for the entire duration of the experiment, exhibiting complete and sustained tumor regression.
“It’s simple,” Dr. Engleman emphasized, encapsulating the clarity of the findings. “If you remove this EPO signaling, either by lowering the hormone levels or by blocking the receptors on the macrophages, you don’t just get a reduction in tumor growth, you get tumor regression along with sensitivity to anti-PD-1 treatment.” This powerful synergy highlights a new avenue for overcoming immunotherapy resistance.
Official Responses: Enthusiasm and Caution
The scientific community is buzzing with excitement over these findings, recognizing their potential to open new therapeutic doors.
Dr. Engleman’s Perspective:
Dr. Engleman’s enthusiasm for the discovery is palpable. His reflections underscore the journey from initial perplexity to profound insight. His acknowledgment of the 2007 FDA black box warning for EPO in cancer patients now gains a critical mechanistic explanation. What was once an unexplained observation of accelerated tumor growth now has a clear immunological basis, fundamentally shifting how clinicians and researchers might view EPO.
“I continue to be amazed by this finding,” Dr. Engleman stated. He acknowledged the complexity of cancer, adding, “Not every tumor is going to respond in the same way, but I’m very optimistic that this discovery will lead to powerful new cancer therapies.”
Collaborative Efforts and Funding:
The research was a collaborative endeavor, with contributions from scientists at the New York Blood Center and the pharmaceutical company ImmunEdge Inc. Funding for this pivotal study was provided by multiple grants from the National Institutes of Health (R01CA262361, P01CA244114, U54CA2745115, and P01HL149626), underscoring its significance within the national research agenda.
Disclosure of Interests:
In adherence to journalistic and scientific transparency, it is important to note the affiliations of the lead researchers. Dr. Chiu is a cofounder of ImmunEdge Inc., and Dr. Engleman is a founder, shareholder, and board member of ImmunEdge Inc. Both Drs. Chiu and Engleman are Stanford-affiliated inventors of PCT/US2023/063997, entitled "EPO receptor agonists and antagonists," indicating their active involvement in translating these discoveries into potential therapeutic applications.
Implications: A New Frontier in Cancer Therapy
The profound implications of this research reverberate across several key areas of oncology, offering renewed hope for patients with currently intractable cancers.
Overcoming Immunotherapy Resistance:
Perhaps the most immediate and significant implication is the potential to render "cold" tumors "hot," thereby extending the benefits of life-saving immunotherapies to a much broader patient population. Many aggressive cancers, including a vast majority of liver, pancreatic, colorectal, and breast cancers, are inherently resistant to checkpoint inhibitors because they lack sufficient immune cell infiltration. Targeting the EPO-macrophage axis could act as a crucial sensitizer, transforming these immune-evading tumors into targets responsive to existing and future immunotherapeutic strategies. This could dramatically improve patient outcomes in diseases where current options are limited.
Designing Novel Therapeutic Strategies:
Dr. Engleman and his colleagues are already actively designing new treatments specifically aimed at targeting EPO signaling in human cancers. Several strategic approaches are being considered:
- Non-specific EPO targeting: One approach involves broadly targeting the EPO protein itself. While this could potentially induce anemia by interfering with red blood cell production, Dr. Engleman speculates that this might be an acceptable trade-off for an effective cancer therapy, particularly in advanced cases where other options have failed. Managing anemia through other interventions could make this a viable strategy.
- Selective blocking of EPO receptors on macrophages: A more refined approach would involve developing drugs that specifically block the EPO receptors exclusively on the surfaces of macrophages within the tumor microenvironment. This strategy aims to disrupt the immunosuppressive signaling cascade without significantly impacting EPO’s erythropoietic functions elsewhere in the body, potentially minimizing side effects. This selective targeting offers a highly promising avenue for precision oncology.
Broad Applicability Across Cancer Types:
While the initial studies focused on liver cancer models, the researchers have strong indications that EPO plays a similar immunosuppressive role in many other types of human cancers. The epidemiological data correlating high EPO levels with poor prognosis in kidney, breast, colon, and skin cancers strongly supports this broader applicability. This suggests that EPO pathway inhibitors could become a versatile new class of anti-cancer agents, applicable to a wide spectrum of solid tumors.
A Fundamental Shift in Understanding:
Beyond immediate therapeutic applications, this discovery represents a fundamental breakthrough in our understanding of how the immune system interacts with cancer. It adds a crucial layer of complexity to the tumor microenvironment, highlighting how cancer cells exploit seemingly innocuous physiological pathways (like red blood cell production) to construct an immune-privileged sanctuary. This expanded knowledge will undoubtedly stimulate further research into other unexpected immune regulatory roles of previously characterized proteins.
Challenges and Future Directions:
While the optimism is high, the path to clinical translation will involve rigorous testing. Pre-clinical validation in diverse human tumor models will be essential. Clinical trials will need to carefully assess efficacy, safety, and optimal dosing regimens for new EPO-targeting agents, either as monotherapies or in combination with existing immunotherapies. Understanding potential off-target effects, especially with non-specific EPO inhibition, will be paramount. Further research will also be needed to explore if other cell types beyond macrophages are influenced by EPO in the tumor microenvironment, and if other EPO-mediated pathways are involved in immune suppression.
In conclusion, the unmasking of EPO as a master regulator of immune evasion marks a pivotal moment in cancer research. By transforming cold tumors into hot, and sensitizing them to immunotherapy, this discovery offers a powerful new weapon in the ongoing fight against cancer, promising to bring hope to countless patients for whom current treatments fall short. The decades-long mystery of EPO’s detrimental link to cancer growth has finally yielded a crucial answer, illuminating a clear path forward for innovative therapeutic development.
About the Author
